serw-MX  [xml]  
 


    
 DeCS Categories

D12 Amino Acids, Peptides, and Proteins .
D12.776 Proteins .
D12.776.543 Membrane Proteins .
D12.776.543.750 Receptors, Cell Surface .
D12.776.543.750.615 Receptor for Advanced Glycation End Products .
D27 Chemical Actions and Uses .
D27.505 Pharmacologic Actions .
D27.505.696 Physiological Effects of Drugs .
D27.505.696.706 Protective Agents .
D27.505.696.706.548 Neuroprotective Agents .
D27.505.696.706.776 Radiation-Protective Agents .
D27.505.954 Therapeutic Uses .
D27.505.954.427 Central Nervous System Agents .
D27.505.954.427.575 Neuroprotective Agents .
D27.720 Specialty Uses of Chemicals .
D27.720.799 Protective Agents .
D27.720.799.763 Radiation-Protective Agents .
 
 Terms
 Synonyms & Historicals
Documents
LILACS e MDL
 
Protective Agents .
Protective Drugs .
Agents, Protective .
Drugs, Protective .
Synthetic or natural substances which are given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. .
1.00
 
Radiation-Protective Agents .
Agents, Radiation-Protective .
Radiation Protectants .
Radiation Protective Agents .
Radiation-Protective Drugs .
Radiation-Protective Effect .
Radiation-Protective Effects .
Radioprotective Drugs .
Agents, Radiation Protective .
Agents, Radioprotective .
Drugs, Radiation-Protective .
Drugs, Radioprotective .
Effect, Radiation-Protective .
Effects, Radiation-Protective .
Protectants, Radiation .
Protective Agents, Radiation .
Radiation Protective Drugs .
Radiation Protective Effect .
Radiation Protective Effects .
Radioprotective Agents .
Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other, e.g. military, purposes. .
0.77
 
Neuroprotective Agents .
Neuroprotectants .
Neuroprotective Drugs .
Neuroprotective Effect .
Neuroprotective Effects .
Agents, Neuroprotective .
Drugs, Neuroprotective .
Effect, Neuroprotective .
Effects, Neuroprotective .
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. .
0.68
 
Receptor for Advanced Glycation End Products .
AGE Receptor .
AGER Protein .
Advanced Glycosylation End Product Receptors .
Advanced Glycosylation End Product-Specific Receptor .
Advanced Glycosylation End-Product Receptor .
Advanced Glycosylation End-Product Receptors .
Advanced Glycosylation Endproduct Receptors .
Amphoterin Receptor .
RAGE (Receptor for Advanced Glycation End Products) .
Receptor for Advanced Glycation End Products (RAGE) .
Receptor for Advanced Glycation Endproducts .
Receptor, Advanced Glycosylation End-Product .
Receptor, Advanced Glycosylation End-Products .
Advanced Glycosylation End Product Receptor .
Advanced Glycosylation End Product Specific Receptor .
Protein, AGER .
Receptor, AGE .
Receptor, Advanced Glycosylation End Product .
Receptor, Advanced Glycosylation End Products .
Receptor, Amphoterin .
A single-pass transmembrane CELL SURFACE RECEPTOR that binds ADVANCED GLYCATION END PRODUCTS to mediate cellular responses to both acute and chronic vascular inflammation in conditions such as ATHEROSCLEROSIS and DIABETES MELLITUS, TYPE 2. It also binds AMYLOID BETA PEPTIDES and the ALARMINS - S100A12 and S100 CALCIUM BINDING PROTEIN BETA SUBUNIT. .
0.67